Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Intern Med J
; 45(1): 94-105, 2015 01.
Article
in En
| MEDLINE
| ID: mdl-25582938
ABSTRACT
The survival of patients with multiple myeloma (MM) has improved substantially since the introduction in the late 1980s of high-dose chemotherapy (HDT) supported by autologous stem cell transplantation (ASCT). Further improvements have been observed following the availability of immunomodulatory drugs (IMiD) such as thalidomide and lenalidomide, and the proteasome inhibitor, bortezomib. Here, we summarise the recommendations of the Medical Scientific Advisory Group to the Myeloma Foundation of Australia for patients considered suitable for HDT + ASCT as part of initial therapy. These recommendations incorporate the various phases of treatment induction, HDT conditioning and maintenance therapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Societies, Scientific
/
Practice Guidelines as Topic
/
Hematopoietic Stem Cell Transplantation
/
Multiple Myeloma
Type of study:
Guideline
Limits:
Humans
Country/Region as subject:
Oceania
Language:
En
Journal:
Intern Med J
Year:
2015
Document type:
Article